MarketBeat
- Home
- MDWD
MDWD
MediWound Ltd.
as of 03-09-2026 3:56pm EST
$17.49
+$0.50
+2.94%
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
| Founded: | 2000 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 224.6M | IPO Year: | 2013 |
| Target Price: | $36.00 | AVG Volume (30 days): | 71.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $14.14 - $22.50 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 57.63% | Revenue Growth (next year): | 26.44% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
Latest MediWound Ltd. News
MDWD Breaking Stock News: Dive into MDWD Ticker-Specific Updates for Smart Investing
GlobeNewswire
MediWound Files Annual Report on Form 20-F
Associated Press Finance
MediWound: Q4 Earnings Snapshot
Compare MDWD vs Leading Stocks
See how MDWD stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MDWD MediWound Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.